SCHEMBL19613799

SCHEMBL19613799

COc1ccc(CN(c2nccs2)S(=O)(=O)c2ccc(NC3CN(C(=O)OC(C)(C)C)CC3C)c(Cl)c2)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 4/20 0.40
SCN1A P35498 3/20 0.40
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
STS P08842 1/20 0.34
MMP1 P03956 2/20 0.34
MMP9 P14780 2/20 0.34
MMP3 P08254 1/20 0.34
MMP7 P09237 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
POLB P06746 1/20 0.34
ADAM17 P78536 2/20 0.34
P2RX3 P56373 1/20 0.33
BMP1 P13497 1/20 0.33
MMP13 P45452 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
ALK Q9UM73 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19613802 1.00 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19631666 1.00 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19614104 1.00 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19614100 1.00 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19613798 1.00 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19631573 1.00 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19627638 0.94 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19627639 0.94 SCN8A (0.40) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19614233 0.93 SCN8A (0.37) SCN8ASCN1ATP53MAPTSTS
SCHEMBL19631557 0.89 CNR1 (0.41) SCN8ASCN1ASTSMMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 US disclosed
CN-109526219-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2021-03-12 CN disclosed
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 US disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 US disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
WO-2017201468-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 WO disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885TP53 1139/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885TP53 1139/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885TP53 1139/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885TP53 1139/4885
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 10/4885SCN1A 1/4885TP53 1402/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885SCN1A 1/4885TP53 1139/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 10/4885SCN1A 1/4885TP53 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.